Abiopharma

🔍 Fukunaga Mark H (Director)

Company: Matson, Inc. (MATX)

Report Date: 2026-04-23

Detailed Transactions and Holdings:

• Acquired 969 shares of Common Stock (Direct)
  Date: 2026-04-23 | Code: A | equity_swap_involved: 0 | shares_owned_after: 30,077.00 | transaction_form_type: 4 | Footnotes: F1

Footnotes:

• F1: Restricted stock units issued under the Issuer's 2025 Incentive Compensation Plan that have 100% cliff vesting on the earlier of the grant date anniversary or the next annual shareholders meeting of the Issuer following the date of the grant of such restricted stock units.